Tvardi Therapeutics Inc.
TVRD | NASDAQ
$1.68
+$0.07 (+4.35%)
Sep 22, 2026, 12:40 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | 7.14M | 20.97M | 41.87M | 23.03M | 135.08M |
Cost of Revenue | 95K | 812K | 6.43M | 7.51M | 1.55M | n/a |
Gross Profit | -95K | 6.33M | 14.54M | 34.35M | 21.47M | n/a |
Operating Income | -26.75M | -55.78M | -121.5M | -87.54M | -89.08M | 5.39M |
Interest Income | 1.38M | 2.83M | 1.32M | 654K | 603K | 2.06M |
Pretax Income | -18.21M | -71.27M | -118.51M | -85.47M | -88.44M | 7.72M |
Net Income | -18.21M | -70.87M | -118.51M | -85.47M | -88.44M | 8.41M |
Selling & General & Admin | 8.74M | 26.39M | 27.65M | 30.13M | 27.98M | 20.94M |
Research & Development | 18.01M | 32.76M | 108.38M | 91.76M | 82.58M | 107.74M |
Other Expenses | n/a | 2.96M | n/a | n/a | n/a | n/a |
Operating Expenses | 26.75M | 62.11M | 136.03M | 121.89M | 110.56M | 128.68M |
Interest Expense | n/a | 8.47M | n/a | 3K | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 26.75M | 62.92M | 142.46M | 129.4M | 112.11M | 129.7M |
Income Tax Expense | n/a | -398K | n/a | n/a | n/a | -691K |
Shares Outstanding (Basic) | 7.42M | 1.52M | 9.36M | 9.36M | 1.41M | 1.32M |
Shares Outstanding (Diluted) | 7.78M | 1.52M | 9.36M | 9.36M | 1.41M | 1.33M |
EPS (Basic) | -2.46 | -46.59 | -1.85 | -2.20 | -62.77 | 6.39 |
EPS (Diluted) | -3.26 | -46.59 | -1.85 | -2.20 | -62.77 | 6.32 |
EBITDA | -18.12M | -62.6M | -117.65M | -83.8M | -86.89M | 8.73M |
EBIT | -18.21M | -62.79M | -117.91M | -85.47M | -88.44M | 7.72M |
Depreciation & Amortization | 95K | 192K | 259K | 1.67M | 1.55M | 1.01M |
Add to Watchlist
Select watchlists to add or remove TVRD